Molecular Analysis for Therapy Choice (MATCH)
This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists.
Contact site for start date.
Please contact ClinicalResearch@sutterhealth.org about Study EAY131.
View study details on ClinicalTrials.gov
Subjects, 18 y/o and older, with histologically documented solid tumors or histologically confirmed diagnosis of lymphoma or multiple myeloma requiring therapy and that has progressed following at least one line of standard systemic therapy and/or for whose disease no standard treatment exists that has been shown to prolong survival
Ari Baron, M.D., Caroline Behler, MD, Bertrand Tuan, MD, Stephanie Jeske, MD, Kevin Kim, MD, Jennifer Guy, M.D., Wei Wang, MD, Alan Kramer, MD, Milana Dolezal, MD, John Chung-Kai Chan, M.D., Lejla Delic, MD, Gauri Kelekar, MD
June 01, 2018